Infliximab Therapy in Iraqi Patients with Moderate to Severe Psoriasis
作者： Hayder R. Al-Hamamy , Ihsan A. Al-Turfy , Farah S. Abdul-Reda
关键词:
摘要: Background: Tumor necrosis factor alpha (TNF-α) is a proinflammatory cytokine which plays critical role in the pathogenesis of psoriasis. Infliximab an anti-TNF-α drug widely used for treatment Objectives: To assess efficacy and safety infliximab Iraqi patients with moderate-to-severe Patients Methods: In this therapeutic, single-center study, total 23 psoriasis resistant to conventional treatments were enrolled receive infusions 5 mg/kg at weeks 0, 2, 6, then every 8 least 22 weeks. Psoriasis Area Severity Index(PASI), Body Surface (BSA) Dermatology Life Quality Index (DLQI) calculated each visit response all side effects recorded. Results: PASI score was reduced from mean ± SD 17.41 8.53 before 2.44 2.68 after At week 22, 84% achieved 75, 42% 90 28% complete clearance. BSA DLQI 35.69 22.44 20.04 4.68 3.52 4.94 3.87 5.60 weeks, respectively. Pruritus, boils, infusion reactions recorded relapse during found 3 patients. Conclusion: monotherapy highly effective psoriasis, rapid onset action relatively low effects.
sci-hub.st 参考文章(12)
A B Gottlieb, Clinical research helps elucidate the role of tumor necrosis factor-αin the pathogenesis of T1-mediated immune disorders: use of targeted immunotherapeutics as pathogenic probes Lupus. ,vol. 12, pp. 190- 194 ,(2003) , 10.1191/0961203303LU354XX
Ali Ahmed Mustafa, Ibrahim A. Al-Hoqail, Biologic systemic therapy for moderate-to-severe psoriasis: A review Journal of Taibah University Medical Sciences. ,vol. 8, pp. 142- 150 ,(2013) , 10.1016/J.JTUMED.2013.09.001
Gerald G. Krueger, Steven R. Feldman, Charles Camisa, Madeleine Duvic, James T. Elder, Alice B. Gottlieb, John Koo, James G. Krueger, Mark Lebwohl, Nicholas Lowe, Alan Menter, Warwick L. Morison, Janet H. Prystowsky, Jerome L. Shupack, J.Richard Taylor, Gerald D. Weinstein, Thomas L. Barton, Tara Rolstadr, Robert M. Day, Two considerations for patients with psoriasis and their clinicians: Journal of the American Academy of Dermatology. ,vol. 43, pp. 281- 285 ,(2000) , 10.1067/MJD.2000.106374
Robert Kalb, Infliximab for the treatment of plaque psoriasis Biologics: Targets & Therapy. ,vol. 2, pp. 115- 124 ,(2008) , 10.2147/BTT.S2116
Luigi Naldi, Epidemiology of psoriasis. Current Drug Targets - Inflammation & Allergy. ,vol. 3, pp. 121- 128 ,(2004) , 10.2174/1568010043343958
James G. Krueger, The immunologic basis for the treatment of psoriasis with new biologic agents Journal of the American Academy of Dermatology. ,vol. 46, pp. 1- 26 ,(2002) , 10.1067/MJD.2002.120568
M Mathur, SK Kedia, RBK Chimire, An intravenous biological therapy for psoriasis: Infliximab Journal of College of Medical Sciences-nepal. ,vol. 7, pp. 69- 72 ,(2012) , 10.3126/JCMSN.V7I1.5977
Enno Christophers, Psoriasis--epidemiology and clinical spectrum. Clinical and Experimental Dermatology. ,vol. 26, pp. 314- 320 ,(2001) , 10.1046/J.1365-2230.2001.00832.X
C.H. Smith, A.V. Anstey, J.N.W.N. Barker, A.D. Burden, R.J.G. Chalmers, D.A. Chandler, A.Y. Finlay, C.E.M. Griffiths, K. Jackson, N.J. McHugh, K.E. McKenna, N.J. Reynolds, A.D. Ormerod, , British Association of Dermatologists’ guidelines for biologic interventions for psoriasis 2009 British Journal of Dermatology. ,vol. 161, pp. 987- 1019 ,(2009) , 10.1111/J.1365-2133.2009.09505.X
C.H. Smith, K. Jackson, S.J. Bashir, A. Perez, A.L. Chew, A.M. Powell, M. Wain, J.N.W.N. Barker, Infliximab for severe, treatment-resistant psoriasis: a prospective, open-label study. British Journal of Dermatology. ,vol. 155, pp. 160- 169 ,(2006) , 10.1111/J.1365-2133.2006.07316.X